The global biomarker discovery outsourcing service market accounted for USD 13.15 billion in 2023 and is expected to reach USD 108.36 billion by 2034 with a CAGR of 21.13% during the forecast period 2024-2034. The market will grow due to factors such as the rising prevalence of chronic diseases, improvements in omics technologies, government initiatives and funding, pharmaceutical and biotechnology R&D expenditures, collaborations and partnerships, and the growing need for personalized medicine.
One important industry driver is the move toward personalized medicine, which primarily uses biomarkers for patient classification and customized therapies. There is a growing need for comprehensive biomarker discovery and validation services as more and more treatment approaches are individualized based on individual biomarker profiles. For instance, Inotiv, Inc. and Synexa Life Sciences announced together in January 2022 that they intended to form a collaboration to further Inotiv's work on important biomarkers for a better understanding of the efficacy and safety of novel biotherapeutics.
By type, the surrogate endpoints segment accounted for the highest revenue-grossing segment in the global biomarker discovery outsourcing service market in 2023 owing to the increased adoption of surrogate endpoints in clinical trials to expedite drug approval processes and reduce development costs. For instance, Australia's Garvan Institute of Medical Research found a new prostate cancer biomarker in October 2022 that may help diagnose and treat individuals with the disease's aggressive type. Additionally, the predictive biomarkers segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for personalized medicine and targeted therapies, along with advancements in technology for biomarker identification and validation.
By therapeutic area, the oncology segment accounted for the highest revenue-grossing segment in the global biomarker discovery outsourcing service market in 2023 owing to the high prevalence of cancer and the significant focus on developing cancer biomarkers for early detection, diagnosis, and personalized treatment strategies. For instance, in 2022, Charles River and Valo Health introduced Logica, an AI-driven drug development system that combines the preclinical knowledge of Charles River with the Valo Opal Computational Platform. Optimizing drug discovery is the goal of the completely controlled risk-sharing paradigm called Logica. Additionally, the autoimmune diseases segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of autoimmune disorders and the growing demand for biomarkers to improve the diagnosis, treatment, and management of these diseases.
By the discovery phase, the biomarker identification segment accounted for the highest revenue-grossing segment in the global biomarker discovery outsourcing service market in 2023 owing to the extensive use of advanced technologies and the critical role of biomarker identification in the early stages of drug development and precision medicine. For instance, HumanFirst, a cloud-based life sciences technology business facilitating precision measurement in patient-centered clinical research, is acquired by ICON in 2024. Additionally, the biomarker validation segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on regulatory compliance, precision medicine initiatives, and the need for reliable biomarkers to guide clinical decision-making and therapeutic development.
By end-user, the biotechnology companies segment accounted for the highest revenue-grossing segment in the global biomarker discovery outsourcing service market in 2023 owing to their extensive investment in research and development, reliance on outsourcing to access specialized expertise and technologies, and the growing demand for biomarkers in drug discovery and development pipelines. For instance, LabCorp announced in December 2023 the introduction of a new range of biomarker development and validation services designed to help oncology and infectious disease precision medicine programs. Additionally, the pharmaceutical company segment is predicted to grow at the fastest CAGR during the forecast period owing to increased outsourcing of biomarker discovery services to streamline drug development processes, expedite time-to-market, and enhance focus on core competencies.
North American region is anticipated to have the highest revenue share during the forecast period owing to its robust healthcare infrastructure, significant investments in research and development, strong regulatory framework, and high adoption rate of advanced biomarker technologies. Additionally, the Asia Pacific region is estimated to grow at the fastest CAGR during the forecast period owing to the increasing healthcare expenditure, rising prevalence of chronic diseases, growing pharmaceutical and biotechnology industries, and expanding outsourcing opportunities for biomarker discovery services. For instance, LabCorp announced in December 2023 the introduction of a new range of biomarker development and validation services designed to help oncology and infectious disease precision medicine programs.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
One important industry driver is the move toward personalized medicine, which primarily uses biomarkers for patient classification and customized therapies. There is a growing need for comprehensive biomarker discovery and validation services as more and more treatment approaches are individualized based on individual biomarker profiles. For instance, Inotiv, Inc. and Synexa Life Sciences announced together in January 2022 that they intended to form a collaboration to further Inotiv's work on important biomarkers for a better understanding of the efficacy and safety of novel biotherapeutics.
By type, the surrogate endpoints segment accounted for the highest revenue-grossing segment in the global biomarker discovery outsourcing service market in 2023 owing to the increased adoption of surrogate endpoints in clinical trials to expedite drug approval processes and reduce development costs. For instance, Australia's Garvan Institute of Medical Research found a new prostate cancer biomarker in October 2022 that may help diagnose and treat individuals with the disease's aggressive type. Additionally, the predictive biomarkers segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for personalized medicine and targeted therapies, along with advancements in technology for biomarker identification and validation.
By therapeutic area, the oncology segment accounted for the highest revenue-grossing segment in the global biomarker discovery outsourcing service market in 2023 owing to the high prevalence of cancer and the significant focus on developing cancer biomarkers for early detection, diagnosis, and personalized treatment strategies. For instance, in 2022, Charles River and Valo Health introduced Logica, an AI-driven drug development system that combines the preclinical knowledge of Charles River with the Valo Opal Computational Platform. Optimizing drug discovery is the goal of the completely controlled risk-sharing paradigm called Logica. Additionally, the autoimmune diseases segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of autoimmune disorders and the growing demand for biomarkers to improve the diagnosis, treatment, and management of these diseases.
By the discovery phase, the biomarker identification segment accounted for the highest revenue-grossing segment in the global biomarker discovery outsourcing service market in 2023 owing to the extensive use of advanced technologies and the critical role of biomarker identification in the early stages of drug development and precision medicine. For instance, HumanFirst, a cloud-based life sciences technology business facilitating precision measurement in patient-centered clinical research, is acquired by ICON in 2024. Additionally, the biomarker validation segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on regulatory compliance, precision medicine initiatives, and the need for reliable biomarkers to guide clinical decision-making and therapeutic development.
By end-user, the biotechnology companies segment accounted for the highest revenue-grossing segment in the global biomarker discovery outsourcing service market in 2023 owing to their extensive investment in research and development, reliance on outsourcing to access specialized expertise and technologies, and the growing demand for biomarkers in drug discovery and development pipelines. For instance, LabCorp announced in December 2023 the introduction of a new range of biomarker development and validation services designed to help oncology and infectious disease precision medicine programs. Additionally, the pharmaceutical company segment is predicted to grow at the fastest CAGR during the forecast period owing to increased outsourcing of biomarker discovery services to streamline drug development processes, expedite time-to-market, and enhance focus on core competencies.
North American region is anticipated to have the highest revenue share during the forecast period owing to its robust healthcare infrastructure, significant investments in research and development, strong regulatory framework, and high adoption rate of advanced biomarker technologies. Additionally, the Asia Pacific region is estimated to grow at the fastest CAGR during the forecast period owing to the increasing healthcare expenditure, rising prevalence of chronic diseases, growing pharmaceutical and biotechnology industries, and expanding outsourcing opportunities for biomarker discovery services. For instance, LabCorp announced in December 2023 the introduction of a new range of biomarker development and validation services designed to help oncology and infectious disease precision medicine programs.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Therapeutic Area, Discovery Phase, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement
Segmentation: Biomarker Discovery Outsourcing Service Market Report 2023 - 2034
Biomarker Discovery Outsourcing Service Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Predictive biomarkers
- Prognostic biomarkers
- Safety biomarkers
- Surrogate endpoints
Biomarker Discovery Outsourcing Service Market Analysis & Forecast by Therapeutic Area 2023 - 2034 (Revenue USD Bn)
- Oncology
- Neurology
- Cardiology
- Autoimmune Diseases
- Others
Biomarker Discovery Outsourcing Service Market Analysis & Forecast by Discovery Phase 2023 - 2034 (Revenue USD Bn)
- Biomarker Identification
- Biomarker Validation
- Biomarker Profiling
- Biomarker Panel Development
- Biomarker Selection
Biomarker Discovery Outsourcing Service Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Pharmaceutical Companies
- Biotechnology Companies
- Others
Biomarker Discovery Outsourcing Service Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Biomarker Discovery Outsourcing Service Market: Type Estimates & Trend Analysis
8. Biomarker Discovery Outsourcing Service Market: Therapeutic Area Estimates & Trend Analysis
9. Biomarker Discovery Outsourcing Service Market: Discovery Phase Estimates & Trend Analysis
10. Biomarker Discovery Outsourcing Service Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Biomarker Discovery Outsourcing Service Market
13. Europe Global Biomarker Discovery Outsourcing Service Market
14. Asia Pacific Global Biomarker Discovery Outsourcing Service Market
15. Latin America Global Biomarker Discovery Outsourcing Service Market
16. MEA Global Biomarker Discovery Outsourcing Service Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Charles River Laboratories
- Eurofins Scientific
- ICON plc
- PPD Inc.
- IQVIA Holdings Inc.
- LabCorp
- Covance Inc. (a subsidiary of LabCorp)
- Q2 Solutions (a joint venture between IQVIA and Quest Diagnostics)
- GenScript Biotech Corporation
- WuXi AppTec
- Caprion Biosciences
- SGS SA
- BioAgilytix Labs
- Frontage Laboratories Inc.
- Protagen AG.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | October 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 13.15 Billion |
| Forecasted Market Value ( USD | $ 108.36 Billion |
| Compound Annual Growth Rate | 21.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
